CRISPR Therapeutics - CRSP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $98.22
  • Forecasted Upside: 86.10%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
▲ +2.31 (4.58%)

This chart shows the closing price for CRSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CRISPR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRSP

Analyst Price Target is $98.22
▲ +86.10% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for CRISPR Therapeutics in the last 3 months. The average price target is $98.22, with a high forecast of $220.00 and a low forecast of $37.00. The average price target represents a 86.10% upside from the last price of $52.78.

This chart shows the closing price for CRSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 polled investment analysts is to buy stock in CRISPR Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2023JMP SecuritiesLower TargetMarket Outperform$100.00 ➝ $70.00Low
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$75.00Low
11/23/2022CitigroupLower TargetNeutral$83.00 ➝ $63.00Low
11/7/2022SVB LeerinkBoost TargetOutperform$75.00 ➝ $76.00Low
11/2/2022Royal Bank of CanadaLower TargetSector Perform$79.00 ➝ $70.00Low
11/2/2022BarclaysLower Target$88.00 ➝ $61.00Low
11/2/2022Credit Suisse GroupLower Target$90.00 ➝ $78.00Low
10/11/2022Morgan StanleyInitiated CoverageUnderweight$37.00Low
8/9/2022Stifel NicolausBoost Target$55.00 ➝ $69.00Low
8/9/2022Chardan CapitalLower TargetBuy$164.00 ➝ $154.00Low
8/9/2022Royal Bank of CanadaLower TargetSector Perform$85.00 ➝ $79.00Low
8/9/2022Credit Suisse GroupBoost TargetNeutral$74.00 ➝ $90.00Low
8/9/2022BarclaysDowngradeOverweight ➝ Equal Weight$99.00 ➝ $88.00Low
8/8/2022SVB LeerinkLower TargetOutperform$112.00 ➝ $107.00Low
8/2/2022CitigroupBoost TargetNeutral$53.00 ➝ $83.00Low
6/23/2022OppenheimerLower TargetOutperform$150.00 ➝ $122.00Low
6/22/2022Stifel NicolausReiterated RatingHold$57.00 ➝ $55.00Low
6/22/2022Chardan CapitalLower TargetBuy$168.00 ➝ $164.00Low
6/22/2022Piper SandlerBoost TargetOverweight$115.00 ➝ $121.00Low
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$98.00High
6/13/2022Stifel NicolausBoost Target$52.00 ➝ $57.00High
5/24/2022The Goldman Sachs GroupLower TargetNeutral$52.00 ➝ $46.00Low
5/23/2022Piper SandlerLower TargetOverweight$180.00 ➝ $115.00Medium
5/17/2022CitigroupLower TargetNeutral$64.00 ➝ $53.00N/A
5/13/2022Needham & Company LLCLower Target$170.00 ➝ $122.00Low
5/11/2022OppenheimerLower Target$172.00 ➝ $150.00High
5/10/2022Royal Bank of CanadaLower Target$95.00 ➝ $85.00High
5/10/2022BarclaysLower Target$107.00 ➝ $99.00High
5/10/2022Chardan CapitalLower Target$171.00 ➝ $168.00High
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$78.00High
3/15/2022CitigroupLower TargetNeutral$90.00 ➝ $64.00Medium
2/17/2022The Goldman Sachs GroupLower TargetNeutral$179.00 ➝ $87.00High
2/16/2022Stifel NicolausLower Target$64.00Low
2/16/2022Truist FinancialReiterated RatingBuy$220.00High
2/16/2022Royal Bank of CanadaLower TargetSector Perform$117.00 ➝ $95.00High
2/16/2022BarclaysLower Target$148.00 ➝ $107.00High
2/16/2022SVB LeerinkLower TargetOutperform$126.00 ➝ $120.00Medium
2/14/2022Brookline Capital AcquisitionInitiated CoverageBuy$143.00High
2/14/2022Brookline Capital ManagementReiterated RatingBuy$143.00High
12/6/2021CowenInitiated CoverageMarket PerformHigh
11/4/2021OppenheimerLower TargetOutperform$185.00 ➝ $172.00Low
11/4/2021BarclaysLower TargetOverweight$160.00 ➝ $148.00High
10/19/2021SVB LeerinkInitiated CoverageOutperform$126.00Medium
10/13/2021Chardan CapitalReiterated RatingBuy$171.00Low
10/13/2021Stifel NicolausLower TargetHold$139.00 ➝ $101.00High
10/13/2021William BlairReiterated RatingBuyMedium
7/30/2021Chardan CapitalLower TargetBuy$175.00 ➝ $171.00High
7/7/2021Chardan CapitalReiterated RatingBuyMedium
6/14/2021CitigroupUpgradeSell ➝ Neutral$55.00 ➝ $132.00Low
5/13/2021Evercore ISIUpgradeOutperformHigh
4/21/2021BarclaysBoost TargetOverweight$140.00 ➝ $160.00High
4/21/2021Jefferies Financial GroupUpgradeHold ➝ Buy$172.00Medium
3/4/2021JMP SecuritiesInitiated CoverageOutperform$160.00High
3/1/2021BarclaysBoost TargetOverweight$113.00 ➝ $140.00Low
2/28/2021BarclaysReiterated RatingBuyLow
2/17/2021The Goldman Sachs GroupLower TargetNeutral$193.00 ➝ $189.00Medium
2/17/2021OppenheimerBoost TargetOutperform$165.00 ➝ $187.00Low
2/17/2021Chardan CapitalBoost TargetBuy$166.00 ➝ $175.00Low
2/17/2021Needham & Company LLCReiterated RatingBuyLow
1/12/2021Truist FinancialBoost Target$170.00 ➝ $210.00Low
12/10/2020Chardan CapitalBoost TargetBuy$110.00 ➝ $166.00High
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
12/10/2020Needham & Company LLCBoost TargetBuy$105.00 ➝ $170.00Medium
12/10/2020Piper SandlerBoost TargetOverweight$107.00 ➝ $180.00Medium
12/7/2020Stifel NicolausBoost TargetHold ➝ Positive$91.00 ➝ $145.00High
12/7/2020OppenheimerBoost TargetOutperform$105.00 ➝ $155.00High
12/7/2020Roth CapitalBoost TargetBuy$115.00 ➝ $170.00High
12/7/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$102.63 ➝ $145.00Low
10/30/2020Raymond JamesReiterated RatingSellHigh
10/29/2020Piper SandlerLower TargetOverweight$128.00 ➝ $107.00Medium
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$110.00 ➝ $110.00Medium
10/22/2020Chardan CapitalBoost TargetPositive ➝ Buy$100.00 ➝ $110.00High
10/21/2020Stifel NicolausBoost TargetHold$75.00 ➝ $93.00Medium
10/21/2020Roth CapitalBoost TargetBuy$105.00 ➝ $115.00High
10/21/2020Piper SandlerBoost TargetOverweight$104.00 ➝ $128.00High
10/5/2020Bank of AmericaInitiated CoverageBuy$110.00 ➝ $110.00High
8/5/2020CitigroupReiterated RatingSellLow
7/28/2020Wells Fargo & CompanyBoost TargetOverweight$95.00 ➝ $110.00High
7/28/2020Chardan CapitalBoost TargetBuy$72.50 ➝ $100.00High
7/28/2020Needham & Company LLCBoost TargetBuy$84.00 ➝ $105.00Medium
7/28/2020William BlairReiterated RatingBuyMedium
7/28/2020BarclaysBoost TargetPositive ➝ Overweight$65.00 ➝ $102.00High
7/27/2020OppenheimerInitiated CoverageBuy$89.00 ➝ $105.00Medium
7/14/2020SunTrust BanksInitiated CoverageBuy$140.00Low
6/23/2020OppenheimerBoost TargetOutperform$80.00 ➝ $89.00High
6/19/2020Piper SandlerReiterated RatingOverweight$104.00High
6/19/2020Roth CapitalBoost TargetBuy$100.00 ➝ $105.00Medium
6/12/2020Piper SandlerReiterated RatingBuy$104.00Medium
6/12/2020Chardan CapitalReiterated RatingBuy$72.50Medium
6/12/2020Needham & Company LLCInitiated CoverageBuy$84.00Medium
6/12/2020OppenheimerInitiated CoverageBuy$80.00Low
5/31/2020Chardan CapitalReiterated RatingBuyMedium
5/6/2020Chardan CapitalReiterated RatingBuyMedium
4/29/2020Needham & Company LLCInitiated CoverageBuy$84.00High
4/28/2020William BlairReiterated RatingBuyHigh
4/1/2020Piper SandlerReiterated RatingBuy$104.00Low
3/4/2020Stifel NicolausInitiated CoverageHold$52.00Low
3/4/2020CitigroupBoost TargetSell$28.00 ➝ $31.00Medium
2/13/2020Piper SandlerReiterated RatingBuy$104.00High
2/13/2020Chardan CapitalReiterated RatingBuy$72.50High
2/13/2020William BlairReiterated RatingBuyHigh
1/30/2020Chardan CapitalReiterated RatingBuyMedium
12/23/2019Needham & Company LLCReiterated RatingBuy$84.00High
12/16/2019Piper Jaffray CompaniesReiterated RatingBuy$104.00Low
12/6/2019Wells Fargo & CompanyReiterated RatingBuyLow
11/26/2019Piper Jaffray CompaniesReiterated RatingBuy$104.00Medium
11/25/2019OppenheimerBoost TargetOutperform$65.00 ➝ $80.00Low
11/19/2019Roth CapitalBoost Target$65.00 ➝ $100.00High
11/19/2019Piper Jaffray CompaniesBoost TargetBuy$100.00 ➝ $107.00High
11/19/2019Wells Fargo & CompanyReiterated RatingBuyHigh
11/19/2019William BlairUpgradeMarket Perform ➝ OutperformHigh
11/19/2019The Goldman Sachs GroupBoost TargetPositive ➝ Neutral$52.00 ➝ $75.00High
11/18/2019Chardan CapitalReiterated RatingBuy$72.50High
11/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$65.00High
10/21/2019Chardan CapitalSet TargetBuy$72.50Low
10/21/2019Piper Jaffray CompaniesReiterated RatingOverweightHigh
10/15/2019Chardan CapitalReiterated RatingBuy$72.50Low
8/1/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$64.00Low
7/31/2019Needham & Company LLCReiterated RatingBuy$62.00Low
7/30/2019Roth CapitalBoost Target$50.00 ➝ $65.00Medium
7/30/2019BarclaysBoost TargetOverweight$59.00 ➝ $62.00Medium
7/30/2019BTIG ResearchBoost TargetBuy ➝ Positive$51.00 ➝ $59.00Medium
7/30/2019William BlairReiterated RatingHoldMedium
6/10/2019Roth CapitalInitiated CoverageBuy$50.00Medium
6/7/2019Chardan CapitalSet TargetBuy$73.00High
5/1/2019Needham & Company LLCReiterated RatingBuy$62.00Medium
4/22/2019BTIG ResearchBoost TargetBuy$30.00 ➝ $33.00Medium
4/11/2019Evercore ISIInitiated CoverageOutperformLow
3/13/2019William BlairInitiated CoverageMarket PerformLow
2/7/2019BTIG ResearchInitiated CoverageBuy$43.00Medium
1/28/2019The Goldman Sachs GroupDowngradeBuy ➝ Neutral$78.00 ➝ $40.00Low
1/22/2019CitigroupDowngradeNeutral ➝ Sell$28.00 ➝ $21.00High
12/31/2018SunTrust BanksReiterated RatingBuyMedium
12/9/2018Needham & Company LLCInitiated CoverageBuy$62.00 ➝ $38.72Low
11/30/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$62.00Medium
10/10/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$65.00High
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/20/2018Raymond JamesInitiated CoverageUnderperform ➝ UnderperformHigh
8/24/2018CitigroupLower TargetNeutral ➝ Neutral$51.00 ➝ $50.00Low
8/8/2018Chardan CapitalReiterated RatingBuy$72.50High
5/15/2018Chardan CapitalBoost TargetBuy$25.00 ➝ $72.50Medium
4/6/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$86.00High
3/9/2018SunTrust BanksReiterated RatingBuy$65.00High
3/9/2018Piper Jaffray CompaniesReiterated RatingOverweight$67.00 ➝ $53.70High
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$69.00High
3/7/2018BarclaysBoost TargetOverweight ➝ Overweight$29.00 ➝ $59.00Low
2/28/2018CitigroupBoost TargetNeutral ➝ Neutral$20.00 ➝ $51.00Medium
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 11 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit
Read More

Today's Range

Now: $52.78
Low: $50.00
High: $53.19

50 Day Range

MA: $48.90
Low: $39.19
High: $55.54

52 Week Range

Now: $52.78
Low: $38.94
High: $86.95


879,864 shs

Average Volume

970,000 shs

Market Capitalization

$4.13 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?

The following Wall Street research analysts have issued research reports on CRISPR Therapeutics in the last twelve months: Barclays PLC, BMO Capital Markets, Brookline Capital Acquisition Corp., Brookline Capital Management, Chardan Capital, Citigroup Inc., Credit Suisse Group AG, EF Hutton Acquisition Co. I, JMP Securities, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus,, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Truist Financial Co..
View the latest analyst ratings for CRSP.

What is the current price target for CRISPR Therapeutics?

18 Wall Street analysts have set twelve-month price targets for CRISPR Therapeutics in the last year. Their average twelve-month price target is $98.22, suggesting a possible upside of 86.1%. Truist Financial Co. has the highest price target set, predicting CRSP will reach $220.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $37.00 for CRISPR Therapeutics in the next year.
View the latest price targets for CRSP.

What is the current consensus analyst rating for CRISPR Therapeutics?

CRISPR Therapeutics currently has 1 sell rating, 6 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRSP will outperform the market and that investors should add to their positions of CRISPR Therapeutics.
View the latest ratings for CRSP.

What other companies compete with CRISPR Therapeutics?

How do I contact CRISPR Therapeutics' investor relations team?

CRISPR Therapeutics' physical mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company's listed phone number is (141) 561-3277 and its investor relations email address is [email protected] The official website for CRISPR Therapeutics is Learn More about contacing CRISPR Therapeutics investor relations.